What the data shows
The recent diagnoses of twins Emma and Bartosz with Spinal Muscular Atrophy (SMA) have raised significant questions about the effectiveness of newborn screening programs in the UK. This situation underscores the critical need for timely diagnosis and intervention in cases of SMA, a genetic disorder that leads to progressive muscle weakness and mobility issues. Emma and Bartosz, who have SMA type 1, the most severe form of the disease, were diagnosed at different times, with Bartosz receiving his diagnosis in 2021 and Emma in 2024.
Both children were diagnosed later than ideal, which has led to concerns about their long-term mobility. According to reports, late diagnoses of SMA can result in an estimated 33 babies in the UK needing a wheelchair due to the progression of the disease. This statistic highlights the urgent need for improved screening protocols, especially as the Scottish government has announced that all babies will soon be screened for SMA as part of the NHS newborn blood spot test.
Emma and Bartosz received the gene therapy Zolgensma through the NHS, which has shown promise in halting the progression of SMA and potentially eradicating it if administered early enough. This treatment has been a beacon of hope for many families affected by SMA, but it also raises questions about access and the timing of diagnosis. The UK currently lags behind other countries, with SMA screening already in place in 46 nations, including the US and much of Europe.
Jesy Nelson, the mother of the twins, has expressed her concerns regarding the late diagnosis and the implications it has for her children’s future. She is not alone; other parents, such as Paola and Rhys Davie, have shared their experiences with SMA, emphasizing the overwhelming nature of the diagnosis and the importance of early intervention. Paola remarked, “It’s awful to think that if I’d decided to give birth in Italy, we probably wouldn’t be having this conversation,” highlighting the disparities in healthcare systems.
Support from the community has been vital for families navigating the challenges of SMA. Urszula, another parent, stated, “I’m sorry you’re going through this. I remember how overwhelming it felt at the beginning.” Such sentiments reflect a growing network of support among families affected by SMA, which can be crucial in managing the emotional and practical challenges posed by the condition.
As the UK prepares for the projected rollout of SMA screening in England by 2031, the experiences of families like Jesy Nelson’s serve as a poignant reminder of the need for immediate action. The late diagnoses of Emma and Bartosz, along with the potential for lifelong mobility issues, underscore the importance of proactive healthcare measures.
While the future holds promise with advancements in gene therapy and the eventual implementation of screening programs, uncertainties remain about the timeline and effectiveness of these initiatives. Details remain unconfirmed regarding the exact rollout dates and the extent of coverage for all newborns in England. The ongoing dialogue about SMA screening and treatment will be crucial as families advocate for better healthcare options.
